ArticleJournal of veterinary internal medicine2026
Evaluation of high flow oxygen therapy in healthy neonatal bull calves.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypoxemia often requires oxygen therapy. Unlike traditional delivery via nasal cannulas, high flow oxygen therapy (HFOT) provides a warm and humidified mixture of medical air and oxygen, and positive inspiratory and end-expiratory pressures in dogs and humans. It has not been evaluated in cattle. HYPOTHESIS/
objectivesHigh flow oxygen therapy will be well tolerated in neonatal bull calves, result in increased oxygenation at all flow rates tested, and produce increased nasopharyngeal pressure at higher flow rates. ANIMALS: Ten healthy neonatal bull calves ≤ 10 days of age.
methodsIn this randomized cross-over study, 2 HFOT devices (Airvo 3 and Volumax) delivered 3 flow rates (0.2, 0.4, and 1.0 L/kg/min). Temperature, heart and respiratory rates, respiratory and tolerance scores, arterial blood gases, nasopharyngeal pressure, end tidal carbon dioxide (ETCO2), and fraction of inspired oxygen (FiO2) were obtained pretreatment and after a 10-min equilibration period at each flow rate. P < .05 was considered a significant change from pretreatment results.
resultsNo differences in respiratory rate (P = .2), heart rate (P = .2), rectal temperature (P = .1), or ETCO2 (P = .1) were detected for any flow rate within each device when compared to pretreatment values. Oxygenation and nasopharyngeal pressure increased as flow rate increased on both devices (P < .05). The PaCO2 increased as flow rate increased for the Airvo 3 (P < .05), but not for the Volumax. CONCLUSIONS AND CLINICAL IMPORTANCE: High flow oxygen therapy was well tolerated in calves and resulted in increased oxygenation at all flow rates and increased nasopharyngeal pressure at higher flow rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.